Drug firms' collaboration pools HIV treatments
Tuesday 03 November 2009
ViiV Healthcare, an unusual collaboration between GlaxoSmithKline and Pfizer, two of the world’s biggest drugs companies, was launched today with a mandate to pool the two firms’ HIV treatments.
ViiV will inherit GSK’s agEing portfolio of HIV medicines, including Combivir, which will lose its patent protection in three year’s time, and Pfizer’s younger and largely untested drugs, such as Selzentry, which ViiV’s chief executive Dominique Limet today described as the company’s “key driver and lever for growth.” Dr Limet takes the helm at ViiV after stepping down as GSK’s head of personalised medicines.
GSK, which is contributing 90 per cent of the £250m start-up costs, will be the major shareholder with an initial 85 per cent of the equity. This also reflects the UK company’s bigger portfolio of marketed drugs, which will initially contribute the most of the new group's revenues.
The equity split will change, however, depending on which company’s medicines and molecules contribute most to profits in the future. The US group has a stronger line of less well developed HIV treatments and will capture a bigger slice of the equity, as much as 30.5 per cent, if its pipeline treatments successfully negotiate clinical trials.
ViiV has 11 marketed medicines and seven molecules in its portfolio.
A number of pharmaceutical groups, including the Swiss giant Roche, have withdrawn from the HIV drug market, blaming increasing difficult commercial conditions.
Dr Limet acknowledged that the market for HIV was challenging: “In truth, we have to get closer to those people who live with the virus,” he said. “Much of our historic effort has been led by the virus – a chase of science. This must continue, but we must also listen and better understand the needs of people living with HIV.”
ViiV has pro forma sales of £1.6bn last year, giving it a 19 per cent market share, behind US group Gilead’s 31 per cent share.
The establishment of ViiV, which was first announced in April, follows GSK’s strategy of concentrating in niche areas, and avoiding costly blockbuster drug research. At the time of the initial announcement GSK’s chief executive Andrew Witty said the deal help the group to guard against the loss of the revenues it will suffer over the next few years as its leading HIV treatments, including Combivir, lose patent protection and are open to competition from generic drug makers.
Newcastle winger is in Argentina having chemotherapy
Returning to the stage after 20 years makes actress feel 'nauseous'
- 1 Scottish independence: Ireland since 1919 is a lesson for Scotland in what a Yes vote means
- 2 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
- 3 Grandmas keep accidentally tagging themselves as Grandmaster Flash on Facebook
- 4 Daniele Watts: Django Unchained actress detained by Los Angeles police after being mistaken for a prostitute
- 5 Kanye West halts concert after two fans don't stand up - doesn't realise one is in wheelchair and the other disabled
Islamic State: Pope is 'being targeted by Isis', Iraqi ambassador to the Holy See warns
Jennifer Lawrence and Kate Upton nude pictures exhibition cancelled after artist concedes photos were 'stolen property'
Scottish independence referendum: A nation divided against itself
John Travolta addresses former pilot's gay romance allegations publicly for the first time: 'That was the lowest I'd ever felt'
Richard III: Two years after his body was found scientists discover how he died
Daniele Watts: Django Unchained actress detained by Los Angeles police after being mistaken for a prostitute
The political class is doing what Hitler couldn’t – destroying Britain
Scottish independence: Nationalist leader Jim Sillars threatens pro-union companies with 'day of reckoning' after independence
Scottish independence: Yes campaign feels the heat as Alex Salmond's NHS claims come under furious attack
Portuguese academic says British are 'filthy, violent and drunk'
£23m Birmingham cycle scheme is attacked by Tory councillor for not catering to the elderly
iJobs Money & Business
£20000 - £25000 per annum + OTE £35,000 first year: SThree: The SThree group i...
£20 - 24k (Uncapped Commission - £35k Year 1 OTE): Guru Careers: We are seekin...
£20 - 24k + Benefits: Guru Careers: This is a great opportunity for an enthusi...
£280 - £320 per day: Ashdown Group: The Ashdown Group have been engaged by a l...